These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 26018996)

  • 1. Disrupting Virchow's triad: can factor X inhibition reduce risk of adverse outcomes in patients with ischaemic cardiomyopathy?
    Ahmad T; Butler J
    Eur J Heart Fail; 2015 Jul; 17(7):647-51. PubMed ID: 26018996
    [No Abstract]   [Full Text] [Related]  

  • 2. Rationale and design of a randomized, double-blind, event-driven, multicentre study comparing the efficacy and safety of oral rivaroxaban with placebo for reducing the risk of death, myocardial infarction or stroke in subjects with heart failure and significant coronary artery disease following an exacerbation of heart failure: the COMMANDER HF trial.
    Zannad F; Greenberg B; Cleland JG; Gheorghiade M; van Veldhuisen DJ; Mehra MR; Anker SD; Byra WM; Fu M; Mills RM
    Eur J Heart Fail; 2015 Jul; 17(7):735-42. PubMed ID: 25919061
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rivaroxaban in Patients with Heart Failure, Sinus Rhythm, and Coronary Disease.
    Zannad F; Anker SD; Byra WM; Cleland JGF; Fu M; Gheorghiade M; Lam CSP; Mehra MR; Neaton JD; Nessel CC; Spiro TE; van Veldhuisen DJ; Greenberg B;
    N Engl J Med; 2018 Oct; 379(14):1332-1342. PubMed ID: 30146935
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Outcomes of Rivaroxaban Monotherapy in Heart Failure Patients With Atrial Fibrillation and Stable Coronary Disease: Insights From the AFIRE Trial.
    Yazaki Y; Nakamura M; Iijima R; Yasuda S; Kaikita K; Akao M; Ako J; Matoba T; Miyauchi K; Hagiwara N; Kimura K; Hirayama A; Matsui K; Ogawa H;
    Circulation; 2021 Oct; 144(17):1449-1451. PubMed ID: 34694893
    [No Abstract]   [Full Text] [Related]  

  • 5. Use of concomitant aspirin in patients with atrial fibrillation: Findings from the ROCKET AF trial.
    Shah R; Hellkamp A; Lokhnygina Y; Becker RC; Berkowitz SD; Breithardt G; Hacke W; Halperin JL; Hankey GJ; Fox KA; Nessel CC; Mahaffey KW; Piccini JP; Singer DE; Patel MR;
    Am Heart J; 2016 Sep; 179():77-86. PubMed ID: 27595682
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rivaroxaban Used for Treatment of a Left Ventricular Thrombus in a Patient With Nonischemic Cardiomyopathy.
    Abubakar H; Yassin AS; Shokr M
    Am J Ther; 2018; 25(6):e706-e709. PubMed ID: 29324466
    [No Abstract]   [Full Text] [Related]  

  • 7. Trial design: Rivaroxaban for the prevention of major cardiovascular events after transcatheter aortic valve replacement: Rationale and design of the GALILEO study.
    Windecker S; Tijssen J; Giustino G; Guimarães AH; Mehran R; Valgimigli M; Vranckx P; Welsh RC; Baber U; van Es GA; Wildgoose P; Volkl AA; Zazula A; Thomitzek K; Hemmrich M; Dangas GD
    Am Heart J; 2017 Feb; 184():81-87. PubMed ID: 27892890
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The factor Xa inhibitor rivaroxaban reduces cardiac dysfunction in a mouse model of myocardial infarction.
    Bode MF; Auriemma AC; Grover SP; Hisada Y; Rennie A; Bode WD; Vora R; Subramaniam S; Cooley B; Andrade-Gordon P; Antoniak S; Mackman N
    Thromb Res; 2018 Jul; 167():128-134. PubMed ID: 29843086
    [TBL] [Abstract][Full Text] [Related]  

  • 9. July 2015 at a glance.
    Metra M
    Eur J Heart Fail; 2015 Jul; 17(7):641. PubMed ID: 26139581
    [No Abstract]   [Full Text] [Related]  

  • 10. Data on trial of anticoagulant is to be reanalyzed after discovery that investigators used faulty device.
    Cohen D
    BMJ; 2015 Dec; 351():h6431. PubMed ID: 26635138
    [No Abstract]   [Full Text] [Related]  

  • 11. The impact of inpatient rivaroxaban versus warfarin on hospital-based outcomes when used for stroke prevention in patients with anticoagulant naïve, new-onset nonvalvular atrial fibrillation.
    Hurley C; Dai S; Sobieraj DM
    Int J Cardiol; 2015 Aug; 192():1-2. PubMed ID: 25981569
    [No Abstract]   [Full Text] [Related]  

  • 12. Questions about the reliability of ROCKET-AF anticoagulation data.
    Christopoulos C
    BMJ; 2016 Feb; 352():i1039. PubMed ID: 26908261
    [No Abstract]   [Full Text] [Related]  

  • 13. [APPLICATION Rivaroxaban for Secondary Stroke Prevention in Clinical Practice. RESULTS OF RUSSIAN Prospective, Multicenter, Observational Study NEURO-XAR].
    Fonyakin On Behalf Of The Working Group Of Researchers AV
    Kardiologiia; 2016 Apr; 56(4):49-53. PubMed ID: 28294859
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: A retrospective analysis of the rivaroxaban once daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF)].
    Divisón Garrote JA; Escobar Cervantes C
    Semergen; 2016; 42(4):260-2. PubMed ID: 26653339
    [No Abstract]   [Full Text] [Related]  

  • 15. Rivaroxaban and Post-Stroke Neurological Outcomes in Patients With Acute Coronary Syndrome.
    Daaboul Y; Korjian S; Plotnikov AN; Burton P; Braunwald E; Wiviott SD; Gibson CM
    J Am Coll Cardiol; 2018 Mar; 71(9):1048-1049. PubMed ID: 29495985
    [No Abstract]   [Full Text] [Related]  

  • 16. Optimizing heart failure management: anticoagulation, diuretic withdrawal, iron substitution, and novel inotropes.
    Lüscher TF
    Eur Heart J; 2019 Nov; 40(44):3579-3582. PubMed ID: 31750530
    [No Abstract]   [Full Text] [Related]  

  • 17. Rivaroxaban: can we trust the evidence?
    Cohen D
    BMJ; 2016 Feb; 352():i575. PubMed ID: 26843102
    [No Abstract]   [Full Text] [Related]  

  • 18. Efficacy and safety of rivaroxaban in real-life patients with atrial fibrillation.
    Barón-Esquivias G; Fernández-Avilés F; Atienza F; Pastor Pueyo P; Toro R; Sanmartín Fernández M
    Expert Rev Cardiovasc Ther; 2015 Apr; 13(4):341-53. PubMed ID: 25797900
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of rivaroxaban in left ventricular thrombi.
    Abdelnaby M; Almaghraby A; Abdelkarim O; Saleh Y; Hammad B; Badran H
    Anatol J Cardiol; 2019 Jan; 21(1):47-50. PubMed ID: 30587707
    [No Abstract]   [Full Text] [Related]  

  • 20. [Good efficacy and safety profile in clinical practice].
    MMW Fortschr Med; 2015 Nov; 157(20):66-7. PubMed ID: 26977521
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.